Clinical Trials Details

A011801 CompassHER2-RD (Breast)

The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DMI and placebo compared to T-DMI and Tucatinib

Clinical Trial Categories

  • Cancers and Other Neoplasms